China's industrial output accelerated and retail sales grew for
the first time this year, beating analysts' forecasts, data
overnight showed.
The yuan surged in both offshore and onshore trading. The
offshore yuan carried on strengthening throughout the European
session, hitting new 16-month highs of 6.7685 versus the U.S.
dollar at 1100 GMT <CNH=EBS>.
The Australian dollar rose after minutes of its central bank
meeting showed no signs of a further cut to record-low interest
rates. At 1111 GMT, it was at 0.73355, up 0.6% on the day <AUD=D3>.
The New Zealand dollar was up 0.4% versus the U.S. dollar <NZD=D3>,
while the Canadian dollar rose around 0.2% <CAD=D3>.
"It's a proper risk-on day today," said Kit Juckes, head of FX
strategy at Societe Generale. "China is an economic winner at
this point in the pandemic."
"There's a sense that the virus is less of a threat in China
now, and also perhaps more widely the market is looking for a
more V-shaped global economic recovery."
The Swedish crown was up around 0.2% at 8.7425 <SEK=D3> while
the Norwegian crown fell around 0.1% <NOK=D3>, taking a hit as
oil prices extended their fall.
The U.S. dollar slipped, although it recovered some of its
overnight losses in early London trade, leaving the dollar index
<=USD> 0.3% lower on the day at 92.801.
U.S. industrial production data is due at 1315 GMT, while the
market is looking ahead to the Federal Reserve's two-day policy
meeting starting on Wednesday.
"Another good August industrial production figure out of the
U.S. today should maintain the positive mood going into
tomorrow's FOMC meeting," ING strategists wrote in a note,
adding the dollar index could still drift down to 92.50.
The euro was up 0.3% versus the dollar at $1.1895 <EUR=EBS>.
Investor sentiment in Germany rose in September, despite
headwinds from Brexit and rising coronavirus infections, the ZEW
economic sentiment survey showed.
The pound rose after better-than-expected jobs data.
The positive sentiment in currency markets was also attributed
to hopes for a COVID-19 vaccine. British drugmaker AstraZeneca
restarted its vaccine trial in Britain on Saturday though it
remains on hold in the United States.
(Reporting by Elizabeth Howcroft; Editing by Kirsten Donovan and
Jan Harvey)
[© 2020 Thomson Reuters. All rights
reserved.] Copyright 2020 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content.
|
|